MHRA approves Astellas’ Vyloy combination for gastric cancer
Most cases go undetected until an advanced stage, as the disease rarely causes early symptoms
Read More
Tag: gastric cancer
AZ, Daiichi Sankyo’s Enhertu wins US approval for HER2-positive gastric cancer
Approval is based on results from the Phase III DESTINY-Gastric01 trial
Read More
Enhertu bags US priority review for HER2+ gastric cancer
FDA action date for regulatory decision set during first quarter of 2021
Read More
BMS’ Opdivo improves survival in gastric and oesophageal cancers
Topline results published from CheckMate-649 and CheckMate-577 studies
Read More
Roche launches HER2 biomarker test for breast and gastric cancer
The test “advances Roche’s commitment to personalised healthcare”.
Read More
AZ announces Phase I DS-8201 results
Approximately one in five breast and gastric cancers are HER2-positive.
Read More
Lilly’s Cyramza fails to improve overall survival in gastric cancer
Eli Lilly’s Cyramza has hit its primary goal in a late-stage study showing extended progression-free survival in patients with gastric cancer, but the drug failed to improve overall survival, a secondary endpoint.
Read More
Avelumab fails to improve survival in gastric cancer
Merck and Pfizer have revealed that a Phase III trial assessing avelumab in patients with gastric cancer after two prior therapeutic regimens failed to hit its primary target of showing an improvement in survival.
Read More
EU nod for first Herceptin biosimilar
European regulators have approved the first biosimilar of Roche’s blockbuster biologic Herceptin, issuing a green light for Samsung Bioepis’ Ontruzant.
Read More
EU regulators to review Herceptin biosimilar
European regulators have agreed to review Samsung Bioepis’ application to market SB3, a biosimilar of Roche’s cancer drug Herceptin.
Read More
AZ Lynparza misses the mark in PhIII gastric cancer trial
AstraZeneca’s Lynparza has failed to hit targets in a Phase III trial assessing its effect on survival in patients with advanced gastric cancer.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
